The rate of secondary malignancies after radical prostatectomy versus external beam radiation therapy for localized prostate cancer: a population-based study on 17,845 patients.

PURPOSE External-beam radiation therapy (EBRT) may predispose to secondary malignancies that include bladder cancer (BCa), rectal cancer (RCa), and lung cancer (LCa). We tested this hypothesis in a large French Canadian population-based cohort of prostate cancer patients. METHODS AND MATERIALS Overall, 8,455 radical prostatectomy (RP) and 9,390 EBRT patients treated between 1983 and 2003 were assessed with Kaplan-Meier and Cox regression analyses. Three endpoints were examined: (1) diagnosis of secondary BCa, (2) LCa, or (3) RCa. Covariates included age, Charlson comorbidity index, and year of treatment. RESULTS In multivariable analyses that relied on incident cases diagnosed 60 months or later after RP or EBRT, the rates of BCa (hazard ratio [HR], 1.4; p = 0.02), LCa (HR, 2.0; p = 0.004), and RCa (HR 2.1; p <0.001) were significantly higher in the EBRT group. When incident cases diagnosed 120 months or later after RP or EBRT were considered, only the rates of RCa (hazard ratio 2.2; p = 0.003) were significantly higher in the EBRT group. In both analyses, the absolute differences in incident rates ranged from 0.7 to 5.2% and the number needed to harm (where harm equaled secondary malignancies) ranged from 111 to 19, if EBRT was used instead of RP. CONCLUSIONS EBRT may predispose to clinically meaningfully higher rates of secondary BCa, LCa and RCa. These rates should be included in informed consent consideration.

[1]  F. Saad,et al.  Poor overall survival in septa- and octogenarian patients after radical prostatectomy and radiotherapy for prostate cancer: a population-based study of 6183 men. , 2008, European urology.

[2]  D. Theodorescu,et al.  Cancer incidence after localized therapy for prostate cancer , 2006, Cancer.

[3]  P. Carroll,et al.  Bladder cancer incidence and risk factors in men with prostate cancer: results from Cancer of the Prostate Strategic Urologic Research Endeavor. , 2007, The Journal of urology.

[4]  U. Capitanio,et al.  High surgical volume is associated with a lower rate of secondary therapy after radical prostatectomy for localized prostate cancer , 2008, BJU international.

[5]  C. Barré.  Open radical retropubic prostatectomy. , 2007, European urology.

[6]  A Bouckaert,et al.  Practical considerations on the use of the Charlson comorbidity index with administrative data bases. , 1996, Journal of clinical epidemiology.

[7]  J. Blasko,et al.  Second malignancies after prostate brachytherapy: incidence of bladder and colorectal cancers in patients with 15 years of potential follow-up. , 2006, International journal of radiation oncology, biology, physics.

[8]  M. Litwin,et al.  Recovery of health related quality of life in the year after radical prostatectomy: early experience. , 1999, The Journal of urology.

[9]  A. Neugut,et al.  Bladder carcinoma and other second malignancies after radiotherapy for prostate carcinoma , 1997, Cancer.

[10]  F. Saad,et al.  High provider volume is associated with lower rate of secondary therapies after definitive radiotherapy for localized prostate cancer. , 2008, European urology.

[11]  F. Saad,et al.  Clinicians are poor raters of life‐expectancy before radical prostatectomy or definitive radiotherapy for localized prostate cancer , 2007, BJU international.

[12]  T. Vuong,et al.  Reporting late rectal toxicity in prostate cancer patients treated with curative radiation treatment. , 2008, International journal of radiation oncology, biology, physics.

[13]  Tom Pickles,et al.  The risk of second malignancy in men with prostate cancer treated with or without radiation in British Columbia, 1984-2000. , 2002, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[14]  U. Capitanio,et al.  Radical prostatectomy for incidental (stage T1a-T1b) prostate cancer: analysis of predictors for residual disease and biochemical recurrence. , 2008, European urology.

[15]  A. Neugut,et al.  The effect of comorbidity and socioeconomic status on sexual and urinary function and on general health-related quality of life in men treated with radical prostatectomy for localized prostate cancer. , 2008, The journal of sexual medicine.

[16]  J. Coebergh,et al.  Bowel, urinary, and sexual problems among long-term prostate cancer survivors: a population-based study. , 2009, International journal of radiation oncology, biology, physics.

[17]  R H Brook,et al.  Quality-of-life outcomes in men treated for localized prostate cancer. , 1995, JAMA.

[18]  D. Kuban,et al.  Uncertainty of calculated risk estimates for secondary malignancies after radiotherapy. , 2007, International journal of radiation oncology, biology, physics.

[19]  D. Kuban,et al.  The calculated risk of fatal secondary malignancies from intensity-modulated radiation therapy. , 2005, International journal of radiation oncology, biology, physics.

[20]  T. Thompson,et al.  Additional surgical intervention after radical prostatectomy, radiation therapy, androgen-deprivation therapy, or watchful waiting. , 2007, European urology.

[21]  D. Brenner,et al.  Second malignancies in prostate carcinoma patients after radiotherapy compared with surgery , 2000, Cancer.

[22]  M. Elhilali,et al.  Thirty-day mortality rates and cumulative survival after radical retropubic prostatectomy. , 1998, Urology.

[23]  L. Collette,et al.  Implications of prostate-specific antigen doubling time as indicator of failure after surgery or radiation therapy for prostate cancer. , 2007, European urology.

[24]  M. Soloway,et al.  Secondary cancer after radiotherapy for prostate cancer: should we be more aware of the risk? , 2007, European urology.

[25]  Joel E Tepper,et al.  Increased risk of rectal cancer after prostate radiation: a population-based study. , 2005, Gastroenterology.

[26]  F. Montorsi,et al.  The effect of surgical volume, age and comorbidities on 30‐day mortality after radical prostatectomy: a population‐based analysis of 9208 consecutive cases , 2008, BJU international.

[27]  G E Hanks,et al.  Quality of life study in prostate cancer patients treated with three-dimensional conformal radiation therapy: comparing late bowel and bladder quality of life symptoms to that of the normal population. , 2001, International journal of radiation oncology, biology, physics.

[28]  Bruno Speleers,et al.  Intensity-modulated radiotherapy as primary therapy for prostate cancer: report on acute toxicity after dose escalation with simultaneous integrated boost to intraprostatic lesion. , 2008, International journal of radiation oncology, biology, physics.

[29]  M Bolla,et al.  EAU guidelines on prostate cancer. , 2001, European urology.

[30]  Ismael Herruzo,et al.  Health-related quality of life 2 years after treatment with radical prostatectomy, prostate brachytherapy, or external beam radiotherapy in patients with clinically localized prostate cancer. , 2008, International journal of radiation oncology, biology, physics.

[31]  S. Fosså,et al.  Long-term morbidity and quality of life in patients with localized prostate cancer undergoing definitive radiotherapy or radical prostatectomy. , 1999, International journal of radiation oncology, biology, physics.

[32]  J. Fowler,et al.  Acute toxicity after hypofractionated conformal radiotherapy for localized prostate cancer: nonrandomized contemporary comparison with standard fractionation. , 2008, International journal of radiation oncology, biology, physics.

[33]  Michel Bolla,et al.  [EAU guidelines on prostate cancer]. , 2009, Actas urologicas espanolas.